| RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines. | |
| | |
MedLine Citation:
|
PMID: 19125251 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: To identify the apoptosis genes involved in the multidrug resistant phenotype of osteosarcoma. METHODS: Multidrug resistant human osteosarcoma cell line (U-2 OS MR) and a drug sensitive parental cell line (U-2 OS) were both treated with paclitaxel and analyzed by the gene array containing 96 apoptosis associated genes. The different expression of the special apoptosis associated genes were further analyzed by Western blot in the multidrug resistant osteosarcoma cell lines (U-2 OS MR, KH OS R2) and the drug sensitive parental cell lines (U-2 OS, KH OS). One of the disregulated gene, RAIDD, was transfected into the multidrug resistant osteosarcoma cells for functional studies. RESULTS: RAIDD showed signs of significant expression in the U-2 OS cells after being treated with paclitaxel (P < 0.01). However, the induction of RAIDD did not occur in U-2 OS MR cells (P = 0.2). Subsequent analysis by Western blot confirmed the deficiency of the expression of RAIDD protein in U-2 OS MR. On the contrary, the expression of RAIDD could be significantly induced by paclitaxel and doxorubicin in U-2 OS cells as both time and dosage were deciding factors. It also demonstrated the cleavage of PARP associated with RAIDD expression in U-2 OS cells, but not however in U-2 OS MR cells after being treated with paclitaxel or doxorubicin. Similar results were found in osteosarcoma multidrug resistant cell line KH OS R2 and the drug sensitive parental cell line KH OS. Furthermore, over-expression of RAIDD in multidrug resistant cell lines could possibly reverse drug resistant phenotypes. CONCLUSION: This study indicate that impaired expression of RAIDD in drug induced apoptosis may play a role in the multidrug resistance of osteosarcoma cells. |
| | |
Authors:
|
Cao Yang; Francis J Hornicek; Kirkham B Wood; Joseph H Schwab; Henry Mankin; Zhenfeng Duan |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2009-01-06 |
Journal Detail:
|
Title: Cancer chemotherapy and pharmacology Volume: 64 ISSN: 1432-0843 ISO Abbreviation: Cancer Chemother. Pharmacol. Publication Date: 2009 Aug |
Date Detail:
|
Created Date: 2009-06-08 Completed Date: 2009-06-25 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7806519 Medline TA: Cancer Chemother Pharmacol Country: Germany |
Other Details:
|
Languages: eng Pagination: 607-14 Citation Subset: IM |
Affiliation:
|
Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA 02114, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibiotics, Antineoplastic
/
pharmacology Antineoplastic Agents, Phytogenic / administration & dosage, pharmacology Apoptosis / genetics* Blotting, Western CRADD Signaling Adaptor Protein / genetics* Cell Line, Tumor Dose-Response Relationship, Drug Doxorubicin / pharmacology Drug Resistance, Multiple Drug Resistance, Neoplasm* Gene Expression Regulation, Neoplastic* Humans Oligonucleotide Array Sequence Analysis / methods Osteosarcoma / genetics* Paclitaxel / administration & dosage, pharmacology Phenotype Poly(ADP-ribose) Polymerases / metabolism Time Factors Transfection |
| Grant Support | |
ID/Acronym/Agency:
|
R01-CA119617/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antibiotics, Antineoplastic; 0/Antineoplastic Agents, Phytogenic; 0/CRADD Signaling Adaptor Protein; 0/CRADD protein, human; 23214-92-8/Doxorubicin; 33069-62-4/Paclitaxel; EC 2.4.2.30/Poly(ADP-ribose) Polymerases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Silencing CD147 inhibits tumor progression and increases chemosensitivity in murine lymphoid neoplas...
Next Document: Work-up of a renal biopsy: what is established? What will follow?